China holds a dominant position in the global photovoltaic cell market, accounting for an astonishing 80% of the total market share. Recent reports indicate that its manufacturing capacity is a staggering 17 times greater than the rest of the world combined . This unparalleled production capacity has prompted the Chinese government to bolster the manufacturing of more than 1,000 GW in N-type cell capacity as international commitments to net emissions standards evolve. As more countries fulfill these commitments, China’s supremacy in the solar energy sector remains largely unchallenged, although India is emerging as a potential disruptor in the long run.
Beyond solar cells, China is also the world’s leading producer of lithium batteries . In the realm of electric vehicles (EVs), it manufactures 57% of the batteries utilized worldwide. Leading the charge are companies like CATL and BYD , which boast a combined market share of 34% and 16% , respectively. This overwhelming dominance in two critical sectors is attributed to a strategic focus on investments in research and development (R&D) and large-scale production, enhancing competitiveness. Now, Chinese biopharmaceutical firms aim to replicate this success formula in the medical sector.
China’s Ability to Drastically Reduce Healthcare Costs
According to Da Liu , Managing Director of the CR-CP Life Science Fund, “We can reduce the costs of medical care and benefit more people through technological innovation and efficiency improvement.” This powerful statement underscores the potential for biotechnology advancements to influence healthcare costs dramatically. The CR-CP Fund is a coalition of the Chinese state and Thailand’s Pokphand Group, formed to invest in promising biotechnology enterprises.
“We can reduce medical care costs and benefit more people through technological innovation and efficiency improvement.”
Chinese pharmaceutical and biotechnology sectors are experiencing a “Deepseek” moment. This term signifies a growing demand from multinational corporations for drugs developed in China rather than starting from scratch. The implications are huge—these global players are eager to obtain licenses to produce or distribute Chinese-developed medicines.
In a recent report by the American investment bank Jefferies , it was highlighted that Chinese companies are exceptionally competitive due to their efficiency in costs, short turnaround times , and the quality of their products. Notably, of the top ten agreements in the pharmaceutical industry during the first half of 2025, seven involved Chinese licenses , according to Pharmcube , a consultancy specializing in pharmaceuticals.
The success of China’s pharmaceutical sector stems from a strategy mirroring the winning tactics in its solar and battery industries. However, challenges loom large. Geopolitical tensions, particularly between the U.S. and China, complicate the international growth prospects for Chinese biotechnology firms. Liu states that to emerge as significant global players in the pharmaceutical field, these companies need to attain a dominant position in at least one or two biotech domains.
Image | Edward Jenner
For more information, visit SCMP.
As China continues to leverage its strengths to gain traction in the global pharmaceutical market, the intersection of biotechnology and healthcare could redefine not only its economy but also global health standards. The increasing demand for affordable medications, driven by rapid technological advancements and production efficiencies, unleashes unprecedented opportunities. However, the path ahead will require navigating complex international relations and ensuring that innovations translate into equitable healthcare for populations worldwide.